First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study

作者：Yi‐Long Wu, Hye Ryun Kim, Ross A. Soo, Qing Zhou, Hiroaki Akamatsu, Gee‐Chen Chang, Chao‐Hua Chiu, Hidetoshi Hayashi, Sang‐We Kim, Yasushi Goto, Terufumi Kato, Jianying Zhou, Victor Lee, Makoto Nishio, Baohui Han, Dong‐Wan Kim, Shun Lü, Anna Polli, Jean-François Martini, Francesca Toffalorio, Chew Hooi Wong, Tony Mok · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/j.jtho.2025.02.021 · 被引用次数：8 · 研究领域：Lung Cancer Treatments and Mutations、Brain Metastases and Treatment、Lung Cancer Research Studies